Here's How ANIP's Rare Disease Portfolio Is Driving Top-line Growth
ANI Pharmaceuticals' rare disease surge, led by Cortrophin Gel, drives major 2025 revenue gains despite softer ophthalmology sales.
Why 2025 is a Dynamic and Transformative Year for Collegium
COLL's bold buybacks, board refresh and expanding ADHD push highlight a year of strategic moves and rising momentum.
ANI ( ANIP ) Loses 15% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for ANI (ANIP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
3 Reasons Why Growth Investors Shouldn't Overlook ANI ( ANIP )
ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
ANI ( ANIP ) Upgraded to Strong Buy: Here's What You Should Know
ANI (ANIP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Patrick D Walsh Executes Sell Order: Offloads $750K In ANI Pharmaceuticals Stock - ANI Pharmaceuticals ( NASDAQ:ANIP )
Patrick D Walsh, Board Member at ANI Pharmaceuticals ( NASDAQ:ANIP ) , executed a substantial insider sell on November 17, according to an SEC filing. What Happened: Walsh opted to sell 8,643 shares of ANI Pharmaceuticals, according to a Form 4 filing with the U.S.
Molina Secures Deal From AHCA to Serve Florida's Medicaid Members
MOH wins sole contract from AHCA to manage care for around 120,000 Florida enrollees of SMMC and CHIP through a Medicaid deal.
ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell?
ANIP's 53% YTD surge fuels strong 2025 financial performance, a raised outlook and powerful momentum in its rare disease portfolio.
Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus
KOD posts a wider Q3 loss as rising R&D spend fuels advances across its eye-disease pipeline ahead of key data readouts.
Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint
NVS' GanLum meets its phase III goal, showing strong efficacy against drug-resistant malaria and proving non-inferiority to the current standard of care.
Should Value Investors Buy ANI Pharmaceuticals ( ANIP ) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is ANI Pharmaceuticals ( ANIP ) Outperforming Other Medical Stocks This Year?
Here is how ANI Pharmaceuticals (ANIP) and Black Diamond (BDTX) have performed compared to their sector so far this year.
ANI Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - London
PRINCETON, N.J., Nov. 11, 2025 ( GLOBE NEWSWIRE ) -- ANI Pharmaceuticals, Inc. ( ANI or the Company ) ( Nasdaq: ANIP ) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference - London on Tuesday, November 18, ...
ANI Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - London - ANI Pharmaceuticals ( NASDAQ:ANIP )
PRINCETON, N.J., Nov. 11, 2025 ( GLOBE NEWSWIRE ) -- ANI Pharmaceuticals, Inc. ( ANI or the Company ) ( NASDAQ:ANIP ) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference - London on Tuesday, November 18, ...
Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y
EDIT reports narrower Q3 loss, boosts revenues on a Bristol Myers milestone, and advances in vivo gene-editing program with EDIT-401.
IOVA Soars 28% on Narrower-Than-Expected Loss in Q3, Revenues Up Y/Y
Iovance's shares jump 28% as the biotech narrows its quarterly loss and lifts gross margins amid strong Amtagvi sales and cost cuts.
Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised
NVAX exceeds third-quarter expectations, boosted by a Sanofi milestone payment. It lifts its 2025 sales outlook.
ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down
Esperion's Q3 loss widens despite a 69% jump in revenues. Mixed results and investor jitters probably drag ESPR shares down 15%.
Allogene Posts Narrower-Than-Expected Loss in Q3, Nil Sales
ALLO's Q3 loss narrows to 19 cents per share, beating estimates, as R&D and G&A costs decline despite no product sales.
PBYI's Q3 Earnings & Revenues Beat Estimates, 2025 Sales View Raised
Puma Biotechnology beats third-quarter estimates for earnings and revenues and lifts its 2025 outlook on stronger Nerlynx sales.
Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y
NKTR posts a narrower Q3 loss and a revenue beat, while its rezpeg program advances with key phase IIb milestones.
Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble
Despite a narrower Q3 loss, NTLA stock plunges after pulling nex-z milestone guidance amid FDA scrutiny in amyloidosis patients.
ANI Pharmaceuticals ( ANIP ) Q3 Earnings and Revenues Beat Estimates
ANI (ANIP) delivered earnings and revenue surprises of +17.24% and +7.81%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance
PRINCETON, N.J., Nov. 07, 2025 ( GLOBE NEWSWIRE ) -- ANI Pharmaceuticals, Inc. ( Nasdaq: ANIP ) ( ANI or the Company ) today announced financial results and business highlights for the third quarter ended September 30, 2025.
Revolution Medicines Posts Wider-Than-Expected Loss in Q3, Sales Nil
RVMD posts a wider Q3 loss as rising R&D and administrative costs weigh, while its RAS(ON) pipeline advances toward key 2026 data.
ACAD Q3 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth
Acadia's third-quarter earnings and revenues top forecasts as Nuplazid and Daybue sales power double-digit annual growth.
TEVA Q3 Earnings & Revenues Beat, Austedo Sales View Raised, Stock Up
Teva stock jumps after third-quarter earnings and revenues top estimates, driven by robust Austedo sales as well as U.S. generics growth.
JAZZ Beats on Q3 Earnings & Sales, Narrows '25 Sales View
Jazz Pharmaceuticals posts strong Q3 results with higher EPS and sales, aided by a tax benefit and robust neuroscience growth.
Catalyst Pharmaceuticals Q3 Earnings Beat, Firdapse Revenues Rise Y/Y
CPRX Q3 earnings and revenues beat estimates, driven by strong Firdapse and Agamree sales, while raising the full-year 2025 total revenue guidance.
RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y
Recursion Pharmaceuticals narrows its Q3 loss but posts lower-than-expected revenues due to reduced collaboration revenues from its partners.
Cytokinetics ( CYTK ) Reports Q3 Loss, Lags Revenue Estimates
Cytokinetics (CYTK) delivered earnings and revenue surprises of +3.14% and -65.18%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Perrigo Q3 Earnings Beat, Sales Miss, Stock Falls on '25 View Cut
PRGO beats Q3 earnings estimates but misses on sales. It also trims the 2025 outlook and launches a strategic review of its infant formula unit.
Waters Q3 Earnings Surpass Estimates, Revenue Increase Y/Y
WAT posts strong Q3 results with 16% earnings growth and higher sales, lifting its full-year outlook for 2025.
VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve?
VRTX's new drugs deliver a mixed Q3 performance. Alyftrek sales surge. Journavx and Casgevy lag expectations but show promise.
MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened
Mirum posts third-quarter profit and stronger revenues on surging Livmarli demand, while tightening its 2025 sales outlook.
Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up
MDGL's wider Q3 loss fails to deter investors, as soaring Rezdiffra sales drive revenues past estimates and lift the stock.
Corcept Q3 Earnings & Revenues Lag Estimates, '25 View Cut, Stock Down
CORT's third-quarter earnings and sales miss estimate. The company cuts guidance despite a 14% year-over-year rise in revenues. Stock falls.
ZTS Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down
Zoetis tops Q3 earnings forecasts but misses on revenues and trims 2025 sales outlook, sending shares lower on weak U.S. results.
Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint
VRTX tops Q3 earnings and revenue estimates on strong Trikafta and Alyftrek sales, but shares slip as Casgevy sales disappoint.
AXSM Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales
Axsome incurs wider-than-expected Q3 loss but revenues soar 63% on booming Auvelity sales, with Sunosi and the newest drug, Symbravo, aiding the top line.
TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised
TG Therapeutics beats third-quarter estimates as a surge in Briumvi sales drives revenues up 92.8% and leads to a higher 2025 outlook.
Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?
RXRX gears up for Q3 results as it refocuses its pipeline and collaboration-driven revenue strategy.
Rigel Gears Up to Report Q3 Earnings: Here's What to Expect
RIGL's rising Tavalisse sales, along with incremental sales from Rezlidhia and Gavreto, could power another earnings beat in the quarter to be reported.
AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues
Agios posts a narrower-than-expected third-quarter loss as Pyrukynd drives a 44% revenue rise, with potential label expansions on the horizon.
Rigel Gears Up to Report Q3 Earnings: Here's What to Expect
RIGL's rising Tavalisse sales, along with incremental sales from Rezlidhia and Gavreto, could power another earnings beat in the quarter to be reported.
Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates
APLS shares plunge 31% despite topping Q3 earnings and revenue estimates, as gains were driven by a one-time Sobi payment.
AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues
Agios posts a narrower-than-expected third-quarter loss as Pyrukynd drives a 44% revenue rise, with potential label expansions on the horizon.
ANI Pharmaceuticals ( ANIP ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ANI Pharmaceuticals ( ANIP ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
